Literature DB >> 23266706

Cardinal role of the intrarenal renin-angiotensin system in the pathogenesis of diabetic nephropathy.

Hiroyuki Kobori1, Masumi Kamiyama, Lisa M Harrison-Bernard, L Gabriel Navar.   

Abstract

Diabetes mellitus is one of the most prevalent diseases and is associated with increased incidence of structural and functional derangements in the kidneys, eventually leading to end-stage renal disease in a significant fraction of afflicted individuals. The renoprotective effects of renin-angiotensin system (RAS) blockade have been established; however, the mechanistic pathways have not been fully elucidated. In this review article, the cardinal role of an activated RAS in the pathogenesis of diabetic nephropathy (DN) is discussed with a focus on 4 themes: (1) introduction to RAS cascade, (2) intrarenal RAS in diabetes, (3) clinical outcomes of RAS blockade in DN, and (4) potential of urinary angiotensinogen as an early biomarker of intrarenal RAS status in DN. This review article provides a mechanistic rational supporting the hypothesis that an activated intrarenal RAS contributes to the pathogenesis of DN and that urinary angiotensinogen levels provide an index of intrarenal RAS activity.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23266706      PMCID： PMC3554867          DOI： 10.2310/JIM.0b013e31827c28bb

Source DB:  PubMed          Journal:  J Investig Med        ISSN： 1081-5589            Impact factor:   2.895


  102 in total

1.  Increased urinary angiotensinogen is precedent to increased urinary albumin in patients with type 1 diabetes.

Authors:  Toshie Saito; Maki Urushihara; Yumiko Kotani; Shoji Kagami; Hiroyuki Kobori
Journal:  Am J Med Sci       Date:  2009-12       Impact factor: 2.378

2.  The brain renin-angiotensin system modulates angiotensin II-induced hypertension and cardiac hypertrophy.

Authors:  O Baltatu; J A Silva; D Ganten; M Bader
Journal:  Hypertension       Date:  2000-01       Impact factor: 10.190

3.  Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes.

Authors:  Minghao Ye; Jan Wysocki; Josette William; Maria José Soler; Ivan Cokic; Daniel Batlle
Journal:  J Am Soc Nephrol       Date:  2006-10-04       Impact factor: 10.121

4.  Intrarenal renin angiotensin system revisited: role of megalin-dependent endocytosis along the proximal nephron.

Authors:  Marcus Pohl; Henriette Kaminski; Hayo Castrop; Michael Bader; Nina Himmerkus; Markus Bleich; Sebastian Bachmann; Franziska Theilig
Journal:  J Biol Chem       Date:  2010-10-21       Impact factor: 5.157

5.  Angiotensin I-converting enzyme activity in tubular fluid along the rat nephron.

Authors:  D E Casarini; M A Boim; R C Stella; M H Krieger-Azzolini; J E Krieger; N Schor
Journal:  Am J Physiol       Date:  1997-03

6.  Urinary angiotensinogen accurately reflects intrarenal Renin-Angiotensin system activity.

Authors:  Maki Urushihara; Shuji Kondo; Shoji Kagami; Hiroyuki Kobori
Journal:  Am J Nephrol       Date:  2010-02-15       Impact factor: 3.754

7.  Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats.

Authors:  Yukiko Nagai; Li Yao; Hiroyuki Kobori; Kayoko Miyata; Yuri Ozawa; Akira Miyatake; Tokihito Yukimura; Takatomi Shokoji; Shoji Kimura; Hideyasu Kiyomoto; Masakazu Kohno; Youichi Abe; Akira Nishiyama
Journal:  J Am Soc Nephrol       Date:  2005-01-12       Impact factor: 10.121

8.  In situ hybridization and immunohistochemistry of renal angiotensinogen in neonatal and adult rat kidneys.

Authors:  I A Darby; C Sernia
Journal:  Cell Tissue Res       Date:  1995-08       Impact factor: 5.249

9.  Changes in single nephron renin release are mediated by tubular fluid flow rate.

Authors:  P P Leyssac
Journal:  Kidney Int       Date:  1986-09       Impact factor: 10.612

10.  Increased blood pressure in transgenic mice expressing both human renin and angiotensinogen in the renal proximal tubule.

Authors:  Julie L Lavoie; Kristy D Lake-Bruse; Curt D Sigmund
Journal:  Am J Physiol Renal Physiol       Date:  2004-01-13
View more
  29 in total

1.  The TetO rat as a new translational model for type 2 diabetic retinopathy by inducible insulin receptor knockdown.

Authors:  Nadine Reichhart; Sergio Crespo-Garcia; Nadine Haase; Michaela Golic; Sergej Skosyrski; Anne Rübsam; Christina Herrspiegel; Norbert Kociok; Natalia Alenina; Michael Bader; Ralf Dechend; Olaf Strauss; Antonia M Joussen
Journal:  Diabetologia       Date:  2016-10-04       Impact factor: 10.122

2.  High-fat diet amplifies renal renin angiotensin system expression, blood pressure elevation, and renal dysfunction caused by Ceacam1 null deletion.

Authors:  Caixia Li; Silas A Culver; Syed Quadri; Kelly L Ledford; Qusai Y Al-Share; Hilda E Ghadieh; Sonia M Najjar; Helmy M Siragy
Journal:  Am J Physiol Endocrinol Metab       Date:  2015-09-15       Impact factor: 4.310

3.  The inhibitory effect of angiotensin II on BKCa channels in podocytes via oxidative stress.

Authors:  Na Gao; Hui Wang; Xiaochen Zhang; Zhuo Yang
Journal:  Mol Cell Biochem       Date:  2014-09-19       Impact factor: 3.396

4.  Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy.

Authors:  Tony Jourdan; Gergő Szanda; Avi Z Rosenberg; Joseph Tam; Brian James Earley; Grzegorz Godlewski; Resat Cinar; Ziyi Liu; Jie Liu; Cynthia Ju; Pál Pacher; George Kunos
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-24       Impact factor: 11.205

Review 5.  Contractile apparatus dysfunction early in the pathophysiology of diabetic cardiomyopathy.

Authors:  Mark T Waddingham; Amanda J Edgley; Hirotsugu Tsuchimochi; Darren J Kelly; Mikiyasu Shirai; James T Pearson
Journal:  World J Diabetes       Date:  2015-07-10

6.  Diminazene aceturate prevents nephropathy by increasing glomerular ACE2 and AT2 receptor expression in a rat model of type1 diabetes.

Authors:  Santosh Kumar Goru; Almesh Kadakol; Vajir Malek; Anuradha Pandey; Nisha Sharma; Anil Bhanudas Gaikwad
Journal:  Br J Pharmacol       Date:  2017-08-11       Impact factor: 8.739

7.  Increased urinary angiotensinogen precedes the onset of albuminuria in normotensive type 2 diabetic patients.

Authors:  Zhen Zhuang; Qiong Bai; Lata A; Yaoxian Liang; Danxia Zheng; Yue Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

8.  Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy.

Authors:  Jay C Jha; Stephen P Gray; David Barit; Jun Okabe; Assam El-Osta; Tamehachi Namikoshi; Vicki Thallas-Bonke; Kirstin Wingler; Cedric Szyndralewiez; Freddy Heitz; Rhian M Touyz; Mark E Cooper; Harald H H W Schmidt; Karin A Jandeleit-Dahm
Journal:  J Am Soc Nephrol       Date:  2014-02-07       Impact factor: 10.121

9.  Chronic angiotensin II infusion drives extensive aldosterone-independent epithelial Na+ channel activation.

Authors:  Mykola Mamenko; Oleg Zaika; Minolfa C Prieto; V Behrana Jensen; Peter A Doris; L Gabriel Navar; Oleh Pochynyuk
Journal:  Hypertension       Date:  2013-09-23       Impact factor: 10.190

10.  Angiotensin and mineralocorticoid receptor antagonism attenuates cardiac oxidative stress in angiotensin II-infused rats.

Authors:  Jacqueline N Minas; Max A Thorwald; Debra Conte; Jose-Pablo Vázquez-Medina; Akira Nishiyama; Rudy M Ortiz
Journal:  Clin Exp Pharmacol Physiol       Date:  2015-11       Impact factor: 2.557
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.